TCR2 Therapeutics hauls in $125 mln Series B

Cambridge, Massachusetts-based TCR2 Therapeutics Inc, an immuno-oncology company, has raised $125 million in Series B funding. The lead investors were 6 Dimensions Capital and Curative Ventures. Other investors in the round included Redmile Group, ArrowMark Partners, Hillhouse Capital Group, MiraeAsset Financial Group, Lucion Group, Sirona Capital, Alexandria Venture Investments, MPM Capital, F2 Ventures and Cathay Fortune Capital Investment.

Source: Press Release